Macquarie Group Ltd. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA)

Macquarie Group Ltd. lowered its stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,307 shares of the company’s stock after selling 141 shares during the period. Macquarie Group Ltd.’s holdings in Moderna were worth $2,047,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA. Evoke Wealth LLC grew its position in Moderna by 100.8% in the third quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock worth $28,000 after acquiring an additional 120 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new position in Moderna in the third quarter worth about $28,000. Legacy CG LLC purchased a new position in Moderna in the second quarter worth about $34,000. Castleview Partners LLC grew its position in Moderna by 14,182.9% in the second quarter. Castleview Partners LLC now owns 4,999 shares of the company’s stock worth $35,000 after acquiring an additional 4,964 shares in the last quarter. Finally, Equitec Proprietary Markets LLC purchased a new position in shares of Moderna during the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 63.11% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 245 shares of the stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the sale, the president now directly owns 1,627,693 shares of the company’s stock, valued at approximately $266,778,882.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, President Stephen Hoge sold 245 shares of the stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the sale, the president now directly owns 1,627,693 shares of the company’s stock, valued at approximately $266,778,882.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 459 shares of the company’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $136.43, for a total transaction of $62,621.37. Following the transaction, the insider now owns 5,243 shares of the company’s stock, valued at approximately $715,302.49. The disclosure for this sale can be found here. Over the last three months, insiders have sold 516,337 shares of company stock valued at $90,666,632. 17.30% of the stock is owned by insiders.

Moderna Price Performance

Shares of MRNA opened at $138.29 on Friday. The firm has a market capitalization of $53.43 billion, a PE ratio of 6.93 and a beta of 1.70. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.73 and a quick ratio of 2.54. Moderna, Inc. has a 1-year low of $115.03 and a 1-year high of $217.25. The company’s fifty day moving average price is $170.31 and its 200-day moving average price is $160.02.

Moderna (NASDAQ:MRNA – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The company reported $3.61 EPS for the quarter, missing the consensus estimate of $4.66 by ($1.05). Moderna had a net margin of 43.41% and a return on equity of 46.34%. The business had revenue of $5.08 billion during the quarter, compared to analysts’ expectations of $5.02 billion. During the same period in the previous year, the company posted $11.29 earnings per share. Moderna’s revenue for the quarter was down 29.5% compared to the same quarter last year. On average, equities research analysts predict that Moderna, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on MRNA. JPMorgan Chase & Co. boosted their target price on Moderna from $132.00 to $138.00 and gave the company a “neutral” rating in a research report on Wednesday, February 8th. Royal Bank of Canada began coverage on Moderna in a research report on Wednesday, March 1st. They set an “outperform” rating and a $200.00 target price for the company. Jefferies Financial Group upgraded Moderna from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $275.00 in a research report on Monday, December 19th. Bank of America boosted their target price on Moderna from $160.00 to $182.00 in a research report on Tuesday, November 15th. Finally, Chardan Capital boosted their target price on Moderna from $191.00 to $208.00 and gave the company a “neutral” rating in a research report on Wednesday, January 18th. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $180.86.

About Moderna

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.